In 2019 Biointelect hosted its second annual medicines policy symposium, this report summarises the main points of the presentation discussing this topic. The main discussions being the challenges of valuation of new oncology medicines, whether oncology submissions are optimal for assessment of value, what is to be learnt from the international discussion on valuation and the perspective of the patients, the ultimate stakeholder.
Strengthening Australia’s Approach to Horizon Scanning for New Therapies
Horizon scanning is a process or system which seeks to